Mandate

Vinge advises Industrifonden in connection with investment in Smartfish

September 18, 2013

Industrifonden is investing SEK 35 million in the Norwegian company, Smartfish, which develops Omega 3 drinks within the field of clinical nutrition. The current owner, Investinor and private investors are also participating in the new issue valued at approximately SEK 80 million. The money will primarily be used for clinical trials and future international expansion. Smartfish develops prescription-based Omega 3-enriched drinks in the form of fruit juice for, e.g. cancer patients, who often develop cachexia, i.e. emaciation caused by significant, long-term malnourishment. At the same time, a new product for Alzheimer patients is being developed. The company holds a patented method which makes it possible to introduce high doses of Omega 3 fatty acid into the juice without affecting its taste.

Smartfish is headquartered in Oslo, although production occurs in Sweden. The company has recently been awarded a procurement contract pertaining to clinical nutrition in Skåne, which will be launched in Sweden this autumn. As a result of the capital infusion, an R&D centre will be established in Stockholm.

The investment in Starfish is the first stage of a recently commenced life science co-operation between Industrifonden and the Norwegian investment enterprise, Investinor. The aim is to give attractive life science companies access to international capital.

Vinge’s team consisted of partner Johan Larsson and associate Alexandra Kempe.   

Related

Vinge has advised Sveafastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Sveafastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 13 June 2025 and the trading on Nasdaq Stockholm commenced on 18 June 2025.
June 18, 2025

Vinge advises Bridgepoint in its acquisition of Safe Life

Vinge advises Bridgepoint in its agreement to acquire a significant controlling stake in Safe Life, a global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.
June 16, 2025

Vinge advises Armada Investment AG on its investment in Studsvik

Armada Investment AG, the Zurich-based entrepreneurial investment firm led by Daniel S. Aegerter, has increased its shareholding in Studsvik to 29.9% of outstanding shares. The investment builds on Armada's initial 9.9% stake acquired in February 2025. The shares of Studsvik are admitted to trading on Nasdaq Stockholm. Armada has invested across the nuclear supply chain for over a decade, with portfolio companies including Oklo, Commonwealth Fusion Systems, Proxima Fusion, Last Energy, and Blykalla.
June 16, 2025